Kalaris Therapeutics Inc Price & Performance (KLRS)

Kalaris Therapeutics has officially completed its merger with AlloVir, marking a significant milestone in the biopharmaceutical sector. The newly merged entity will trade on Nasdaq under the ticker KLRS starting March 19, 2025. This merger provides Kalaris with $100 million in cash to advance its retinal disease treatment pipeline, including the novel TH103 therapy.123

AlloVir and Kalaris Therapeutics have secured shareholder approval for their merger, paving the way for the launch of groundbreaking treatments for retinal diseases. The combined company, named Kalaris Therapeutics, aims to address unmet needs in the market with its lead candidate, TH103, targeting neovascular Age-related Macular Degeneration.23

The merger between AlloVir and Kalaris Therapeutics highlights a strategic move in the ophthalmology sector. The combined company, operating as Kalaris Therapeutics, brings enhanced resources to develop TH103, a promising anti-VEGF therapy. With $100 million in post-merger funding, the company is set to accelerate clinical trials into 2026.13